Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 4
1993 6
1994 5
1995 8
1996 5
1997 5
1998 2
1999 3
2000 2
2001 1
2002 4
2004 2
2005 3
2006 6
2007 7
2008 5
2009 6
2010 3
2011 1
2012 3
2013 2
2014 6
2015 4
2016 6
2017 3
2018 5
2019 9
2020 11
2021 12
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

129 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.
ECFS best practice guidelines: the 2018 revision.
Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. Castellani C, et al. Among authors: heijerman hgm. J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. J Cyst Fibros. 2018. PMID: 29506920 Free article. Review.
CFTR Modulators: Does One Dose Fit All?
van der Meer R, Wilms EB, Heijerman HGM. van der Meer R, et al. Among authors: heijerman hgm. J Pers Med. 2021 May 24;11(6):458. doi: 10.3390/jpm11060458. J Pers Med. 2021. PMID: 34073663 Free PMC article. Review.
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
Berkers G, van der Meer R, Heijerman H, Beekman JM, Boj SF, Vries RGJ, van Mourik P, Doyle JR, Audhya P, Yuan ZJ, Kinnman N, van der Ent CK. Berkers G, et al. Among authors: heijerman h. J Cyst Fibros. 2021 Sep;20(5):761-767. doi: 10.1016/j.jcf.2020.11.007. Epub 2020 Nov 26. J Cyst Fibros. 2021. PMID: 33249003 Free article. Clinical Trial.
Prevention of drug-related complications in cystic fibrosis.
van der Meer R, Touw DJ, Heijerman HGM. van der Meer R, et al. Among authors: heijerman hgm. Curr Opin Pulm Med. 2019 Nov;25(6):666-673. doi: 10.1097/MCP.0000000000000625. Curr Opin Pulm Med. 2019. PMID: 31503211 Review.
Clinical trials in cystic fibrosis.
Döring G, Elborn JS, Johannesson M, de Jonge H, Griese M, Smyth A, Heijerman H; Consensus Study Group. Döring G, et al. Among authors: heijerman h. J Cyst Fibros. 2007 Apr;6(2):85-99. doi: 10.1016/j.jcf.2007.02.001. J Cyst Fibros. 2007. PMID: 17350898 Free article. Review.
Transparency and diversity in cystic fibrosis research - Authors' reply.
McCoy KS, Heijerman H, Taylor-Cousar JL, Waltz D, Sosnay PR, Ramsey BW, Rowe S, Welter J. McCoy KS, et al. Among authors: heijerman h. Lancet. 2020 Aug 29;396(10251):602. doi: 10.1016/S0140-6736(20)30897-7. Lancet. 2020. PMID: 32861305 No abstract available.
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis.
Berkers G, van Mourik P, Vonk AM, Kruisselbrink E, Dekkers JF, de Winter-de Groot KM, Arets HGM, Marck-van der Wilt REP, Dijkema JS, Vanderschuren MM, Houwen RHJ, Heijerman HGM, van de Graaf EA, Elias SG, Majoor CJ, Koppelman GH, Roukema J, Bakker M, Janssens HM, van der Meer R, Vries RGJ, Clevers HC, de Jonge HR, Beekman JM, van der Ent CK. Berkers G, et al. Among authors: heijerman hgm. Cell Rep. 2019 Feb 12;26(7):1701-1708.e3. doi: 10.1016/j.celrep.2019.01.068. Cell Rep. 2019. PMID: 30759382 Free article.
129 results